PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Status:
Completed
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from
microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been
used to treat patients that have cancers that have arginine. In this study, the primary
efficacy variable will be assessment of tumor response rate.